Results 1 to 10 of about 2,401 (204)

Physiologically‐Based Pharmacokinetic Model‐Informed Labeling for Cariprazine Drug Interactions With CYP3A Inhibitors [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Cariprazine is a potent D3‐preferring dopamine D3/D2 receptor partial agonist, a serotonin 5‐HT1A receptor partial agonist, and a serotonin 5‐HT2B receptor antagonist approved for the treatment of a variety of psychiatric disorders.
Md Mahbubul Huq Riad, Patrick Marroum, Mohamad Shebley, Hao Xiong   +3 more
doaj   +3 more sources

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy [PDF]

Neuropsychiatric Disease and Treatment, 2018
Leslie Citrome Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA Abstract: Cariprazine is an oral antipsychotic approved in the US and EU for the treatment of schizophrenia.
Leslie Citrome
exaly   +5 more sources

Cariprazine Use in Early Psychosis: Three Case Reports [PDF]

Frontiers in Psychiatry, 2021
Objective: Cariprazine is a new atypical antipsychotic approved for the acute and maintenance treatment of schizophrenia (1, 2) and for the treatment of manic or mixed episodes associated with bipolar I disorder (1).
Ricardo Coentre, Ricardo Coentre, Rodrigo Saraiva, Rodrigo Saraiva, Carolina Sereijo, Pedro Levy   +5 more
doaj   +2 more sources

Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data

Therapeutic Advances in Psychopharmacology, 2020
Cariprazine is one of the newest dopamine-serotonin partial agonists, also known as ‘atypical’ second generation antipsychotics. Originally approved for acute and maintenance treatment of schizophrenia as well as for acute mania and mixed mania ...
Debbi Morrissette
exaly   +2 more sources

Real-World Disability Outcomes Among Patients Treated with Cariprazine vs Other Atypical Antipsychotics as Adjunctive Treatment for Major Depressive Disorder [PDF]

ClinicoEconomics and Outcomes Research
Prakash S Masand,1 Mousam Parikh,2 Jamie T Ta,2 Sally W Wade,3 Filmon Haile,2 Susannah Ripley,4 Enrico Zanardo,5 Colleen S Spencer,4 François Laliberté,4 Nadia Nabulsi2 1Duke-NUS, Singapore; 2AbbVie, North Chicago, IL, USA; 3Wade Outcomes Research and ...
Masand PS, Parikh M, Ta JT, Wade SW, Haile F, Ripley S, Zanardo E, Spencer CS, Laliberté F, Nabulsi N   +9 more
doaj   +2 more sources

Cariprazine augmentation for negative symptoms of schizophrenia: a prospective analysis and literature review [PDF]

Therapeutic Advances in Psychopharmacology
Cariprazine is effective in a number of conditions and has shown efficacy in the treatment of negative symptoms. Data on its use as an adjunct to other antipsychotics is growing.
Ewa Okon-Rocha, David Taylor
doaj   +2 more sources

Efficacy and Clinical Relevance of Adjunctive Cariprazine Treatment in Patients with Major Depressive Disorder: Post Hoc Analyses from a Phase III Study [PDF]

Neuropsychiatric Disease and Treatment
George I Papakostas,1 Prakash S Masand,2 Anita H Clayton,3 Vladimir Maletic4 ,† Julie L Adams,5 Ludmyla Rekeda,6 Manpreet Kaur Singh,7 Majid Kerolous8 1Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; 2Academic Medicine ...
Papakostas GI, Masand PS, Clayton AH, Maletic V, Adams JL, Rekeda L, Singh MK, Kerolous M   +7 more
doaj   +2 more sources

Symptomatic Profile of Cariprazine in the Context of ICD-11 Domains for Schizophrenia: Review of Clinically Oriented Studies [PDF]

Consortium Psychiatricum, 2022
INTRODUCTION: One of the innovations in the ICD-11grouping "Schizophrenia and Other Primary Psychotic Disorders" is the implementation of six symptom domains intended to improve diagnostics and treatment of these mental conditions in clinical practice ...
Alexey Viktorovich Pavlichenko, Anna Sergeevna Gubina   +1 more
doaj   +1 more source

Clinical Global Impression of Cariprazine in Negative Symptom Schizophrenia Patients: Comparison of clinical trial data vs. real-world evidence

European Psychiatry, 2023
Introduction There is an increasing need to understand the effectiveness of novel medications in real-world context since despite being the gold standard, double-blind trials have their own limitations as well.
E. Rancans, Z. B. Dombi, R. Csehi, G. Németh   +3 more
doaj   +1 more source

Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials

Frontiers in Psychiatry, 2021
Bipolar disorder (BD) is chronic psychiatric disorder associated with significant impairment in psychosocial functioning and quality of life. Although current pharmacological treatments for BD have improved its clinical management, many patients do not ...
André Do, Kamyar Keramatian, Ayal Schaffer, Lakshmi Yatham   +3 more
doaj   +1 more source